Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Probucol, a new cholesterol lowering drug

D T Nash

    Journal of Medicine
    |January 1, 1975
    PubMed
    Summary

    This study assessed Dh-581 (Procubol) for long-term serum cholesterol reduction and its effects on triglycerides. Results indicate sustained effectiveness and good tolerance for daily dosing.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diabetes mellitus and cardiovascular disease.

    The Diabetes educator·2002
    Same author

    Effectiveness of medical therapy alone compared with coronary angioplasty or left internal mammary artery bypass for single-vessel coronary artery disease.

    The American journal of cardiology·2001
    Same author

    Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.

    Archives of internal medicine·2000
    Same author

    Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.

    Journal of the American College of Cardiology·1999
    Same author

    Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

    Circulation·1998
    Same author

    A conversation between two cardiologists.

    The American journal of cardiology·1996

    Area of Science:

    • Cardiovascular pharmacology
    • Lipid metabolism research

    Background:

    • Elevated serum cholesterol poses significant cardiovascular risks.
    • Effective and safe long-term lipid-lowering agents are crucial for disease management.

    Purpose of the Study:

    • To evaluate the efficacy of Dh-581 (Procubol) in reducing serum cholesterol over extended periods.
    • To assess the sustained effectiveness of Dh-581 in maintaining cholesterol reduction.
    • To investigate the impact of Dh-581 on triglyceride levels and its safety profile.

    Main Methods:

    • Long-term administration of Dh-581 (Procubol).
    • Monitoring of serum cholesterol and triglyceride levels.
    • Assessment of drug safety and patient tolerance to daily doses.

    Main Results:

    • Dh-581 demonstrated the ability to reduce serum cholesterol levels effectively over extended durations.
    • The cholesterol-lowering effect of Dh-581 was maintained without a loss of potency.
    • DH-581 showed favorable effects on triglycerides and was well-tolerated in daily doses.

    Conclusions:

    • Dh-581 (Procubol) is a promising agent for long-term management of hypercholesterolemia.
    • Sustained cholesterol reduction and favorable triglyceride effects support its therapeutic potential.
    • The safety and tolerance profile suggest suitability for daily therapeutic use.

    Related Experiment Videos